280 related articles for article (PubMed ID: 15622317)
1. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
5. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
7. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
[TBL] [Abstract][Full Text] [Related]
8. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
9. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
12. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
[TBL] [Abstract][Full Text] [Related]
13. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
[TBL] [Abstract][Full Text] [Related]
14. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
15. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
16. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
18. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
19. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
[TBL] [Abstract][Full Text] [Related]
20. Pediatric HIV costs across three treatment eras from 1986 to 2007.
Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
